For CRC no bsAb therapy is currently approved; however, a bispecific carcinoembryonic antigen (CEA) × CD3 antibody was evaluated in a phase I clinical trial (NCT02291614), with 28% of patients achieving stable disease as their best response [17]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.